Share Price and Basic Stock Data
Last Updated: February 10, 2026, 10:09 pm
| PEG Ratio | -1.52 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemcrux Enterprises Ltd operates in the specialty chemicals sector, focusing on various products. The company’s revenue for FY 2023 stood at ₹95.15 Cr, slightly declining from ₹95.27 Cr in FY 2022. The latest quarterly sales recorded for September 2023 were ₹15.84 Cr, reflecting a downward trend from ₹22.29 Cr in June 2023. The sales trajectory indicates fluctuations, with a significant peak in FY 2022. The trailing twelve months (TTM) sales stood at ₹70.69 Cr, showing a contraction compared to previous years. The overall sales pattern suggests that while Chemcrux has experienced substantial growth in the past, recent quarters indicate challenges in maintaining revenue momentum. With 23,478 shareholders, the company has a diverse ownership base, which may influence its strategic decisions. The company’s ability to adapt to market dynamics will be crucial for future growth as it navigates these revenue fluctuations in a competitive sector.
Profitability and Efficiency Metrics
Chemcrux reported a net profit of ₹3.18 Cr for FY 2025, down from ₹4.19 Cr in FY 2024. The operating profit margin (OPM) for the latest fiscal year stood at 12.91%, a decline from 17.04% in FY 2024. This reduction in OPM highlights challenges in cost management and pricing power. The company’s return on equity (ROE) was recorded at 5.36%, significantly lower than the industry average, indicating less efficiency in generating profits from shareholders’ equity. The interest coverage ratio (ICR) stood at 6.14x, suggesting that Chemcrux can comfortably meet its interest obligations. However, the cash conversion cycle (CCC) increased to 137.76 days, indicating potential inefficiencies in inventory management and receivables collection. Overall, while Chemcrux maintains a reasonable ICR, its profitability metrics and efficiency ratios reveal areas needing improvement to enhance shareholder returns.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chemcrux Enterprises reflects a total equity capital of ₹14.81 Cr alongside reserves of ₹62.52 Cr as of September 2025. The company reported borrowings of ₹23.73 Cr, indicating a total debt-to-equity ratio of 0.55x, which is relatively moderate. The book value per share stood at ₹50.39, demonstrating a solid foundation of shareholder equity. The current ratio of 2.31x indicates good liquidity, allowing the company to cover its short-term obligations comfortably. However, the return on capital employed (ROCE) was recorded at 7.11%, significantly lower than historical levels, raising concerns about the efficiency of capital utilization. The financial ratios overall suggest that while Chemcrux has a reasonable capital structure, the declining ROCE and increasing debt levels could pose risks to long-term financial health. The ability to manage debt while maintaining profitability will be pivotal for sustaining operations.
Shareholding Pattern and Investor Confidence
Chemcrux has a stable shareholding structure, with promoters holding 72.92% as of September 2025, indicating strong control and commitment from the management. The public shareholding stood at 27.07%, reflecting a modest level of retail investor participation. Over the past year, the number of shareholders has decreased from approximately 32,559 in September 2023 to 23,478, which may signal waning investor confidence or strategic selling by retail investors. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests limited institutional interest, which could impact the stock’s liquidity and perceived stability. The consistent promoter holding, however, may reassure existing shareholders of the management’s long-term vision. Maintaining investor confidence will be essential as Chemcrux navigates operational challenges while striving for growth in a competitive market.
Outlook, Risks, and Final Insight
The outlook for Chemcrux Enterprises is cautiously optimistic, contingent on its ability to reverse the declining revenue and profitability trends. Key strengths include a solid promoter holding and a manageable debt level, which can support strategic initiatives. However, the company faces risks such as increasing competition in the specialty chemicals sector, declining profit margins, and inefficiencies in working capital management. To improve its financial standing, Chemcrux must focus on enhancing operational efficiencies and exploring new market opportunities. The company could also benefit from diversifying its product offerings to mitigate risks associated with market fluctuations. In a scenario where Chemcrux successfully addresses its operational challenges and improves its profitability metrics, it may regain investor confidence and stabilize its financial performance. Conversely, continued revenue decline without strategic intervention could lead to further erosion of shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 381 Cr. | 41.5 | 65.4/35.0 | 23.7 | 20.5 | 0.96 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.0 Cr. | 63.2 | 88.8/52.0 | 14.8 | 89.6 | 1.58 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.5 Cr. | 728 | 899/600 | 16.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,300 Cr. | 72.8 | 111/68.2 | 21.8 | 22.0 | 0.69 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 610 Cr. | 243 | 373/208 | 23.3 | 93.8 | 1.03 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 13,082.72 Cr | 748.00 | 59.13 | 182.97 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.74 | 20.50 | 20.01 | 22.29 | 15.84 | 21.81 | 18.54 | 17.11 | 17.76 | 19.42 | 15.97 | 16.75 | 18.55 |
| Expenses | 21.94 | 15.47 | 14.90 | 18.43 | 13.50 | 17.43 | 15.92 | 15.05 | 15.40 | 16.73 | 14.03 | 15.16 | 16.88 |
| Operating Profit | 5.80 | 5.03 | 5.11 | 3.86 | 2.34 | 4.38 | 2.62 | 2.06 | 2.36 | 2.69 | 1.94 | 1.59 | 1.67 |
| OPM % | 20.91% | 24.54% | 25.54% | 17.32% | 14.77% | 20.08% | 14.13% | 12.04% | 13.29% | 13.85% | 12.15% | 9.49% | 9.00% |
| Other Income | 0.32 | 0.31 | 0.18 | 0.18 | 0.24 | 0.56 | 0.35 | 0.39 | 0.26 | 0.61 | 0.28 | 0.61 | 0.80 |
| Interest | 0.13 | 0.07 | 0.47 | 0.31 | 0.21 | 0.17 | 0.13 | 0.13 | 0.33 | 0.60 | 0.58 | 0.52 | 0.52 |
| Depreciation | 0.48 | 0.54 | 0.58 | 0.57 | 0.58 | 0.58 | 0.55 | 0.56 | 0.73 | 0.92 | 0.91 | 0.95 | 0.96 |
| Profit before tax | 5.51 | 4.73 | 4.24 | 3.16 | 1.79 | 4.19 | 2.29 | 1.76 | 1.56 | 1.78 | 0.73 | 0.73 | 0.99 |
| Tax % | 26.86% | 24.31% | 31.13% | 26.27% | 30.17% | 36.75% | 3.49% | 29.55% | 26.28% | 25.84% | 35.62% | 19.18% | 18.18% |
| Net Profit | 4.03 | 3.58 | 2.92 | 2.33 | 1.24 | 2.66 | 2.21 | 1.24 | 1.15 | 1.33 | 0.47 | 0.58 | 0.80 |
| EPS in Rs | 2.72 | 2.42 | 1.97 | 1.57 | 0.84 | 1.80 | 1.49 | 0.84 | 0.78 | 0.90 | 0.32 | 0.39 | 0.54 |
Last Updated: December 27, 2025, 2:04 pm
Below is a detailed analysis of the quarterly data for Chemcrux Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 18.55 Cr.. The value appears strong and on an upward trend. It has increased from 16.75 Cr. (Jun 2025) to 18.55 Cr., marking an increase of 1.80 Cr..
- For Expenses, as of Sep 2025, the value is 16.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.16 Cr. (Jun 2025) to 16.88 Cr., marking an increase of 1.72 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.67 Cr.. The value appears strong and on an upward trend. It has increased from 1.59 Cr. (Jun 2025) to 1.67 Cr., marking an increase of 0.08 Cr..
- For OPM %, as of Sep 2025, the value is 9.00%. The value appears to be declining and may need further review. It has decreased from 9.49% (Jun 2025) to 9.00%, marking a decrease of 0.49%.
- For Other Income, as of Sep 2025, the value is 0.80 Cr.. The value appears strong and on an upward trend. It has increased from 0.61 Cr. (Jun 2025) to 0.80 Cr., marking an increase of 0.19 Cr..
- For Interest, as of Sep 2025, the value is 0.52 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.52 Cr..
- For Depreciation, as of Sep 2025, the value is 0.96 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.95 Cr. (Jun 2025) to 0.96 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.99 Cr.. The value appears strong and on an upward trend. It has increased from 0.73 Cr. (Jun 2025) to 0.99 Cr., marking an increase of 0.26 Cr..
- For Tax %, as of Sep 2025, the value is 18.18%. The value appears to be improving (decreasing) as expected. It has decreased from 19.18% (Jun 2025) to 18.18%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 0.80 Cr.. The value appears strong and on an upward trend. It has increased from 0.58 Cr. (Jun 2025) to 0.80 Cr., marking an increase of 0.22 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.54. The value appears strong and on an upward trend. It has increased from 0.39 (Jun 2025) to 0.54, marking an increase of 0.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.61 | 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 78.47 | 70.25 | 70.69 |
| Expenses | 14.05 | 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 65.10 | 61.18 | 62.80 |
| Operating Profit | 1.56 | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 13.37 | 9.07 | 7.89 |
| OPM % | 9.99% | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 17.04% | 12.91% | 11.16% |
| Other Income | 0.03 | 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.18 | 1.53 | 2.30 |
| Interest | 0.45 | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 0.83 | 1.64 | 2.22 |
| Depreciation | 0.50 | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.29 | 3.13 | 3.74 |
| Profit before tax | 0.64 | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 11.43 | 5.83 | 4.23 |
| Tax % | 31.25% | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | 26.16% | 28.13% | |
| Net Profit | 0.43 | 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 8.44 | 4.19 | 3.18 |
| EPS in Rs | 0.80 | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 5.70 | 2.83 | 2.15 |
| Dividend Payout % | 0.00% | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% | 17.55% | 35.35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 97.67% | 104.71% | -13.79% | 57.33% | 294.92% | 14.16% | -16.07% | 66.41% | -3.36% | -41.23% | -50.36% |
| Change in YoY Net Profit Growth (%) | 0.00% | 7.03% | -118.50% | 71.13% | 237.58% | -280.75% | -30.23% | 82.48% | -69.77% | -37.86% | -9.13% |
Chemcrux Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 4% |
| 3 Years: | -10% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -17% |
| 3 Years: | -35% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | -34% |
| 1 Year: | -45% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.80 | 1.80 | 1.80 | 4.94 | 4.94 | 4.94 | 4.94 | 4.94 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | 4.00 | 4.76 | 6.77 | 7.54 | 9.75 | 18.92 | 27.48 | 35.92 | 39.87 | 51.60 | 57.45 | 61.30 | 62.52 |
| Borrowings | 3.46 | 2.69 | 3.61 | 4.00 | 3.73 | 2.94 | 1.92 | 0.93 | 9.11 | 14.43 | 26.46 | 26.81 | 23.73 |
| Other Liabilities | 4.53 | 4.62 | 2.96 | 4.11 | 8.37 | 11.81 | 10.20 | 6.90 | 19.32 | 12.38 | 11.15 | 9.23 | 11.66 |
| Total Liabilities | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 | 112.72 |
| Fixed Assets | 6.94 | 7.07 | 7.54 | 8.29 | 10.75 | 11.24 | 15.40 | 19.37 | 24.32 | 33.11 | 33.09 | 57.55 | 57.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 | 0.31 | 21.06 | 1.61 | 3.92 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 1.07 | 3.89 | 6.53 | 9.35 | 7.09 | 16.79 | 19.83 | 19.84 | 16.51 |
| Other Assets | 6.80 | 6.75 | 7.55 | 12.04 | 14.97 | 23.48 | 22.61 | 19.65 | 51.70 | 43.01 | 35.89 | 33.15 | 35.25 |
| Total Assets | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 | 112.72 |
Below is a detailed analysis of the balance sheet data for Chemcrux Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.81 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.81 Cr..
- For Reserves, as of Sep 2025, the value is 62.52 Cr.. The value appears strong and on an upward trend. It has increased from 61.30 Cr. (Mar 2025) to 62.52 Cr., marking an increase of 1.22 Cr..
- For Borrowings, as of Sep 2025, the value is 23.73 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 26.81 Cr. (Mar 2025) to 23.73 Cr., marking a decrease of 3.08 Cr..
- For Other Liabilities, as of Sep 2025, the value is 11.66 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.23 Cr. (Mar 2025) to 11.66 Cr., marking an increase of 2.43 Cr..
- For Total Liabilities, as of Sep 2025, the value is 112.72 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 112.15 Cr. (Mar 2025) to 112.72 Cr., marking an increase of 0.57 Cr..
- For Fixed Assets, as of Sep 2025, the value is 57.04 Cr.. The value appears to be declining and may need further review. It has decreased from 57.55 Cr. (Mar 2025) to 57.04 Cr., marking a decrease of 0.51 Cr..
- For CWIP, as of Sep 2025, the value is 3.92 Cr.. The value appears strong and on an upward trend. It has increased from 1.61 Cr. (Mar 2025) to 3.92 Cr., marking an increase of 2.31 Cr..
- For Investments, as of Sep 2025, the value is 16.51 Cr.. The value appears to be declining and may need further review. It has decreased from 19.84 Cr. (Mar 2025) to 16.51 Cr., marking a decrease of 3.33 Cr..
- For Other Assets, as of Sep 2025, the value is 35.25 Cr.. The value appears strong and on an upward trend. It has increased from 33.15 Cr. (Mar 2025) to 35.25 Cr., marking an increase of 2.10 Cr..
- For Total Assets, as of Sep 2025, the value is 112.72 Cr.. The value appears strong and on an upward trend. It has increased from 112.15 Cr. (Mar 2025) to 112.72 Cr., marking an increase of 0.57 Cr..
Notably, the Reserves (62.52 Cr.) exceed the Borrowings (23.73 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.90 | -0.48 | -0.46 | -0.55 | 1.00 | 11.24 | 12.86 | 11.63 | 11.60 | 7.03 | -13.09 | -17.74 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59.63 | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 | 71.17 | 63.44 |
| Inventory Days | 159.97 | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 | 99.63 | 127.16 |
| Days Payable | 146.63 | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 | 70.84 | 52.84 |
| Cash Conversion Cycle | 72.96 | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 | 99.96 | 137.76 |
| Working Capital Days | 8.18 | 8.94 | 21.80 | 34.20 | 43.17 | 47.68 | 52.48 | 67.69 | 37.51 | 67.28 | 55.49 | 50.09 |
| ROCE % | 11.87% | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% | 13.46% | 7.11% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Diluted EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Cash EPS (Rs.) | 4.81 | 7.25 | 11.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Revenue From Operations / Share (Rs.) | 47.27 | 52.98 | 64.25 |
| PBDIT / Share (Rs.) | 7.24 | 9.82 | 15.20 |
| PBIT / Share (Rs.) | 5.07 | 8.28 | 13.82 |
| PBT / Share (Rs.) | 3.89 | 7.72 | 13.27 |
| Net Profit / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| NP After MI And SOA / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| PBDIT Margin (%) | 15.30 | 18.54 | 23.64 |
| PBIT Margin (%) | 10.72 | 15.62 | 21.50 |
| PBT Margin (%) | 8.22 | 14.56 | 20.64 |
| Net Profit Margin (%) | 5.58 | 10.76 | 15.08 |
| NP After MI And SOA Margin (%) | 5.58 | 10.76 | 15.08 |
| Return on Networth / Equity (%) | 5.24 | 11.68 | 21.62 |
| Return on Capital Employeed (%) | 7.01 | 12.65 | 25.13 |
| Return On Assets (%) | 3.08 | 7.68 | 14.49 |
| Long Term Debt / Equity (X) | 0.37 | 0.29 | 0.18 |
| Total Debt / Equity (X) | 0.55 | 0.35 | 0.23 |
| Asset Turnover Ratio (%) | 0.59 | 0.75 | 0.00 |
| Current Ratio (X) | 2.31 | 3.88 | 3.34 |
| Quick Ratio (X) | 1.81 | 3.23 | 2.54 |
| Inventory Turnover Ratio (X) | 7.60 | 2.25 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 37.84 | 35.07 | 20.62 |
| Dividend Payout Ratio (CP) (%) | 20.80 | 27.60 | 18.06 |
| Earning Retention Ratio (%) | 62.16 | 64.93 | 79.38 |
| Cash Earning Retention Ratio (%) | 79.20 | 72.40 | 81.94 |
| Interest Coverage Ratio (X) | 6.14 | 17.48 | 27.50 |
| Interest Coverage Ratio (Post Tax) (X) | 3.24 | 11.14 | 18.54 |
| Enterprise Value (Cr.) | 189.29 | 402.43 | 448.23 |
| EV / Net Operating Revenue (X) | 2.70 | 5.13 | 4.71 |
| EV / EBITDA (X) | 17.66 | 27.66 | 19.92 |
| MarketCap / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| Retention Ratios (%) | 62.15 | 64.92 | 79.37 |
| Price / BV (X) | 2.00 | 5.29 | 6.62 |
| Price / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| EarningsYield | 0.02 | 0.02 | 0.03 |
After reviewing the key financial ratios for Chemcrux Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.25 (Mar 24) to 4.81, marking a decrease of 2.44.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 47.27. It has decreased from 52.98 (Mar 24) to 47.27, marking a decrease of 5.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.24. This value is within the healthy range. It has decreased from 9.82 (Mar 24) to 7.24, marking a decrease of 2.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 8.28 (Mar 24) to 5.07, marking a decrease of 3.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.89. This value is within the healthy range. It has decreased from 7.72 (Mar 24) to 3.89, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For PBDIT Margin (%), as of Mar 25, the value is 15.30. This value is within the healthy range. It has decreased from 18.54 (Mar 24) to 15.30, marking a decrease of 3.24.
- For PBIT Margin (%), as of Mar 25, the value is 10.72. This value is within the healthy range. It has decreased from 15.62 (Mar 24) to 10.72, marking a decrease of 4.90.
- For PBT Margin (%), as of Mar 25, the value is 8.22. This value is below the healthy minimum of 10. It has decreased from 14.56 (Mar 24) to 8.22, marking a decrease of 6.34.
- For Net Profit Margin (%), as of Mar 25, the value is 5.58. This value is within the healthy range. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 8. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 11.68 (Mar 24) to 5.24, marking a decrease of 6.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.01. This value is below the healthy minimum of 10. It has decreased from 12.65 (Mar 24) to 7.01, marking a decrease of 5.64.
- For Return On Assets (%), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 5. It has decreased from 7.68 (Mar 24) to 3.08, marking a decrease of 4.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.37. This value is within the healthy range. It has increased from 0.29 (Mar 24) to 0.37, marking an increase of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.55, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has decreased from 0.75 (Mar 24) to 0.59, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has decreased from 3.88 (Mar 24) to 2.31, marking a decrease of 1.57.
- For Quick Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 3.23 (Mar 24) to 1.81, marking a decrease of 1.42.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 7.60, marking an increase of 5.35.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.84. This value is within the healthy range. It has increased from 35.07 (Mar 24) to 37.84, marking an increase of 2.77.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.80. This value is within the healthy range. It has decreased from 27.60 (Mar 24) to 20.80, marking a decrease of 6.80.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.16. This value is within the healthy range. It has decreased from 64.93 (Mar 24) to 62.16, marking a decrease of 2.77.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.20. This value exceeds the healthy maximum of 70. It has increased from 72.40 (Mar 24) to 79.20, marking an increase of 6.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.14. This value is within the healthy range. It has decreased from 17.48 (Mar 24) to 6.14, marking a decrease of 11.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 11.14 (Mar 24) to 3.24, marking a decrease of 7.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 189.29. It has decreased from 402.43 (Mar 24) to 189.29, marking a decrease of 213.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has decreased from 5.13 (Mar 24) to 2.70, marking a decrease of 2.43.
- For EV / EBITDA (X), as of Mar 25, the value is 17.66. This value exceeds the healthy maximum of 15. It has decreased from 27.66 (Mar 24) to 17.66, marking a decrease of 10.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For Retention Ratios (%), as of Mar 25, the value is 62.15. This value is within the healthy range. It has decreased from 64.92 (Mar 24) to 62.15, marking a decrease of 2.77.
- For Price / BV (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.29 (Mar 24) to 2.00, marking a decrease of 3.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemcrux Enterprises Ltd:
- Net Profit Margin: 5.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.01% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 40.2 (Industry average Stock P/E: 59.13)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.55
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 330, Trivia Complex, Vadodra Gujarat 390007 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Girishkumar C Shah | Executive Chairman |
| Mr. Sanjay Marathe | Managing Director |
| Mr. Vipul Sanghvi | Executive Director |
| Mr. Sidhdhi G Shah | Non Executive Director |
| Mr. Shailesh Patel | Independent Director |
| Mr. Bhanubhai Patel | Independent Director |
| Mr. Nayankumar Shah | Independent Director |
| Mr. Rohit Kothari | Independent Director |
FAQ
What is the intrinsic value of Chemcrux Enterprises Ltd?
Chemcrux Enterprises Ltd's intrinsic value (as of 10 February 2026) is ₹66.75 which is 37.62% lower the current market price of ₹107.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹158 Cr. market cap, FY2025-2026 high/low of ₹170/91.5, reserves of ₹62.52 Cr, and liabilities of ₹112.72 Cr.
What is the Market Cap of Chemcrux Enterprises Ltd?
The Market Cap of Chemcrux Enterprises Ltd is 158 Cr..
What is the current Stock Price of Chemcrux Enterprises Ltd as on 10 February 2026?
The current stock price of Chemcrux Enterprises Ltd as on 10 February 2026 is ₹107.
What is the High / Low of Chemcrux Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemcrux Enterprises Ltd stocks is ₹170/91.5.
What is the Stock P/E of Chemcrux Enterprises Ltd?
The Stock P/E of Chemcrux Enterprises Ltd is 40.2.
What is the Book Value of Chemcrux Enterprises Ltd?
The Book Value of Chemcrux Enterprises Ltd is 52.2.
What is the Dividend Yield of Chemcrux Enterprises Ltd?
The Dividend Yield of Chemcrux Enterprises Ltd is 0.94 %.
What is the ROCE of Chemcrux Enterprises Ltd?
The ROCE of Chemcrux Enterprises Ltd is 7.11 %.
What is the ROE of Chemcrux Enterprises Ltd?
The ROE of Chemcrux Enterprises Ltd is 5.36 %.
What is the Face Value of Chemcrux Enterprises Ltd?
The Face Value of Chemcrux Enterprises Ltd is 10.0.